Business Segments

6 Months Ended

Jun. 30, 2011

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

Note 9. Business Segments

The Company maintains two active business segments: BioTherapeutics and BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended June 30,
	2011			2010
Revenues, Principally from Grants
BioDefense	$	335,029		$	338,104
BioTherapeutics		70,791			106,538
Total	$	405,820		$	444,642
Loss from Operations
BioDefense	$	(67,425	)	$	(133,730	)
BioTherapeutics		(1,663,402	)		(1,237,500	)
Corporate		(201,963	)		(209,040	)
Total	$	(1,932,790	)	$	(1,580,270	)
Amortization and Depreciation Expense
BioDefense	$	10,183		$	13,966
BioTherapeutics		43,290			25,097
Corporate		542			465
Total	$	54,015		$	39,528
Interest Income, Net
Corporate	$	1,473		$	2,977
Stock-Based Compensation
BioDefense	$	18,416		$	12,941
BioTherapeutics		188,255			27,006
Corporate		25,198			20,655
Total	$	231,869		$	60,602

	Six Months Ended June 30,
	2011			2010
Revenues, Principally from Grants
BioDefense	$	871,615		$	601,894
BioTherapeutics		342,210			178,544
Total	$	1,213,825		$	780,438
Income (Loss) from Operations
BioDefense (1)	$	52		$	(725,156	)
BioTherapeutics		(3,044,729	)		(2,379,256	)
Corporate		(610,959	)		(612,486	)
Total	$	(3,655,636	)	$	(3,716,898	)
Amortization and Depreciation Expense
BioDefense	$	19,872		$	37,075
BioTherapeutics		84,491			47,718
Corporate		1,080			986
Total	$	105,443		$	85,779
Interest Income, Net
Corporate	$	3,908		$	3,345
Stock-Based Compensation
BioDefense	$	36,832		$	25,881
BioTherapeutics		286,508			54,269
Corporate		65,296			42,715
Total	$	388,636		$	122,865

(1)    During the six months ended June 30, 2010, the Company incurred $378,501 in a one-time patent write off cost related to its anticipated return of the botulinum toxin vaccine license and abandonment of related patents. This cost is reflected in research and development expense in the consolidated statement of operations.

	As of June 30,  2011		As of December 31, 2010
Identifiable Assets
BioDefense	$	693,399	$	480,995
BioTherapeutics		896,468		927,973
Corporate		4,263,042		7,859,579
Total	$	5,852,909	$	9,268,547